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Introduction {#sec001}
============

Emergence of community-acquired multi-drug-resistant bacterial infections poses a grave public health threat. Urinary tract infections (UTIs) are a major proportion of community-acquired infections that have demonstrated increasing patterns of antimicrobial resistance. UTIs occur in 2--10% of pregnant women, which may be symptomatic or asymptomatic \[[@pone.0232710.ref001]\]. Regardless of symptoms, untreated or undertreated bacteriuria in pregnancy increases risk for adverse outcomes including preterm birth, low birth weight, and pyelonephritis, which can lead to excess maternal and neonatal morbidity and mortality \[[@pone.0232710.ref002]--[@pone.0232710.ref004]\]. Thus, screening and treating pregnant women for bacteriuria has become a routine part of prenatal care \[[@pone.0232710.ref005], [@pone.0232710.ref006]\]. Evaluating the bacteriological profiles of bacteriuria in pregnant women attending antenatal clinics provides an opportunity to study the prevalence of antimicrobial resistance in community-acquired uropathogens and determine appropriateness of empiric treatment options.

Cephalosporins and combination beta-lactam/beta-lactamase inhibitors are considered first-line therapy in the treatment of bacteriuria in pregnancy. Similarly, cephalosporins and fluoroquinolones are frequently used for treating community-acquired UTIs in non-pregnant adults due to their potency, broad spectrum of activity, oral bioavailability, and safety profile \[[@pone.0232710.ref007]\]. However, with increasing antibiotic resistance worldwide, the efficacy of these antibiotic treatment options may be threatened.

Extended-spectrum beta-lactamases (ESBLs) are a group of genetic mutations that confer resistance by hydrolysing penicillins, first-, second-, and third-generation cephalosporins, and aztreonam. They can be inhibited by beta-lactamase inhibitors. ESBLs are encoded by three major groups of genes: *TEM*, *SHV*, and *CTX-M* \[[@pone.0232710.ref008]\], and these enzymes are often found in *Escherichia coli* and *Klebsiella pneumoniae* \[[@pone.0232710.ref009]\]. Several different species of bacteria are capable of producing ESBLs, which were initially associated with healthcare-associated infections (HCAIs), but are increasingly being associated with community-acquired infections.

Fluoroquinolones are used to treat UTIs caused by both gram-positive and gram-negative bacteria. Wide usage of these antibiotics has led to resistance, especially among Enterobacteriaceae \[[@pone.0232710.ref010]\]. Fluoroquinolone resistance varies from 2.2% to 69% among community-acquired UTIs \[[@pone.0232710.ref011]\]. The emergence of plasmid-mediated quinolone resistance (PMQR) was first found in a strain of *K*. *pneumonia* in the USA in 1998 and shown to be due to a member of the pentapeptide repeat family of proteins qnr \[[@pone.0232710.ref012]\]. Qnr interacts with DNA gyrase and topoisomerase IV to prevent quinolone inhibition. In subsequent years, several distantly-related plasmid-mediated qnr determinants have been described in Enterobacteriaceae (*qnrB*, *qnrC*, *qnrD*, *qnrS*). The qnr genes are usually integrated into plasmids, which make them particularly susceptible to cross-species transmission \[[@pone.0232710.ref013]\]. In addition, these plasmids often harbor other antibiotic resistance genes such as ESBLs and favor the selection and dissemination of fluoroquinolone-resistant strains by chemically unrelated drug classes and vice versa \[[@pone.0232710.ref014]\].

There is limited information regarding the frequency of ESBL and fluoroquinolone-resistance genes in community-acquired infections in India. Therefore, this study aimed to uncover the epidemiology of PMQR and ESBL genes in gram-negative bacilli among primigravid women with bacteriuria attending the antenatal clinic for the first time.

Materials and methods {#sec002}
=====================

Study design and sampling {#sec003}
-------------------------

A cross-sectional observational study was conducted at Gandhi Medical College and Hospital, Hyderabad from October 1, 2015 to September 30, 2016. We collected urine specimens from primigravid women attending their first antenatal clinic visit at the outpatient department of Gandhi Hospital. We excluded multigravid and primigravid women who previously attended antenatal clinics to rule out the possibility of any HCAIs or colonization resulting from healthcare exposure. In addition, we administered surveys regarding community exposures at the time of enrollment that indicated recent antibiotic use was rare among study participants \[[@pone.0232710.ref015]\]. The study was approved by IRB committees from Gandhi Medical College and Hospital, Stanford University, and the Indian Council of Medical Research. We also obtained written informed consent from all study participants before specimen collection and interviews.

A structured case proforma was filled by a trained investigator during the antenatal visit. The questionnaire was based on the Demographic and Health Surveys tool AMR Module for Population-Based Surveys \[[@pone.0232710.ref016]\]. The questionnaire included their usual and current residence, occupation, husband's occupation, household income, religion, caste, education level, dietary and hygiene practices, and recent non vitamin tablet consumption. As most of the women were unaware of the antimicrobial drug use, ingestion of any other tablet other than vitamin was the question asked for antimicrobial drug use.

Antimicrobial susceptibility testing {#sec004}
------------------------------------

We performed phenotypic antimicrobial susceptibility testing and ESBL and quinolone resistance screening using a VITEK-2 system in accordance with CLSI guidelines \[[@pone.0232710.ref017]\].

Genotypic characterization of ESBL and PMQR genes {#sec005}
-------------------------------------------------

We targeted ESBL-producing and fluoroquinolone-resistant isolates for detection of ESBL-encoding genes (*TEM*, *SHV*, *CTX-M*) and PMQR-encoding genes (*qnrA*, *qnrB*, *qnrD*, *qnrS*, *aac (6')-Ib-cr*), respectively. We isolated DNA from bacterial cells by using a boiling method. For polymerase chain reaction (PCR) amplification, we prepared master mix using 10 μl dNTPs, 2μl of each primer, 1 μl of Taq polymerase in 6.5 μl PCR buffer, and 22 μl of RNase-free water. We added DNA to the above mixture to a final volume of 50 μl \[[@pone.0232710.ref018]\], utilizing published primers (Tables [1](#pone.0232710.t001){ref-type="table"} and [2](#pone.0232710.t002){ref-type="table"}) \[[@pone.0232710.ref019], [@pone.0232710.ref020]\]. We performed amplification in a thermocycler according to the following cycling parameters: initial denaturation step at 95°C for 5minutes, 35 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 2 minutes, final extension step at 72°C for 10 minutes, and a hold at 4°C. We subjected amplified PCR products to agarose gel electrophoresis with 1.8% agarose gel using suitable molecular weight markers. We visualized the gel on a UV platform in a gel documentation system (Figs [1](#pone.0232710.g001){ref-type="fig"} and [2](#pone.0232710.g002){ref-type="fig"}).

![Gel electrophoresis detection of ESBL-producing genes among *E*. *coli* and *K*. *pneumoniae* isolates.\
Results by lane: 1- ladder (100bp); 2- *K*. *pneumoniae* (ATCC 700603) *CTX-M-15*+*SHV-38* genes; 3-*E*. *coli* (ATCC 25922); 4-Undetected; 5,6,10,14,17- *CTX-M-15*+*SHV-38* genes; 13,15,20- *SHV-38* gene; 7,16,19- *CTX-M-15* +*TEM-1* genes; 8,11,12,18- *TEM-1* gene.](pone.0232710.g001){#pone.0232710.g001}

![Gel electrophoresis detection of PMQR genes among *E*. *coli* and *K*. *pneumoniae* isolates.\
Results by lane: 1- ladder (100bp); 2- ladder (50bp); 3- *K*. *pneumonia qnrB+aac (6')-lb-cr* genes; 4- *qnrS*+*aac (6')-lb-cr* genes; 5,6,15- *aac (6')-lb-cr* genes; 7--14- *qnrS* gene; 16-Undetected.](pone.0232710.g002){#pone.0232710.g002}

10.1371/journal.pone.0232710.t001

###### Primers for polymerase chain reaction of ESBL genes.

![](pone.0232710.t001){#pone.0232710.t001g}

  Primer    Orientation                       Oligonucleotide sequence (5΄-3΄)   Size (bp)
  --------- --------------------------------- ---------------------------------- -----------
  *CTX-M*   Forward                           `5'- GAAGGTCATCAAGAAGGTGCG -3'`    560bp
  Reverse   `5'- GCATTGCCACGCTTTTCATAG- 3'`                                      
  *TEM*     Forward                           `5'—GAGACAATAACCCTGGTAAAT- 3'`     459 bp
  Reverse   `5'- AGAAGTAAGTTGGCAGCAGTG- 3'`                                      
  *SHV*     Forward                           `5'-GTCAGCGAAAAACACCTTGCC- 3'`     383bp
  Reverse   `5'-GTCTTATCGGCGATAAACCAG- 3'`                                       

10.1371/journal.pone.0232710.t002

###### Primers for polymerase chain reaction of PMQR genes.

![](pone.0232710.t002){#pone.0232710.t002g}

  Primer             Orientation               Oligonucleotide sequence (5΄-3΄)   Size (bp)   Annealing Temperature
  ------------------ ------------------------- ---------------------------------- ----------- -----------------------
  *qnrA*             Forward                   `CAGCAAGAGGATTTCTCACG`             630 bp      58°C
  Reverse            `AATCCGGCAGCACTATTACTC`                                                  
  *qnrB*             Forward                   `GGCTGTCAGTTCTATGATCG`             488 bp      59.1°C
  Reverse            `SAKCAACGATGCCTGGTAG`                                                    
  *qnrD*             Forward                   `CGAGATCAATTTACGGGGAATA`           581 bp      57°C
  Reverse            `AACAAGCTGAAGCGCCTG`                                                     
  *qnrS*             Forward                   `GCAAGTTCATTGAACAGGGT`             428 bp      55.6°C
  Reverse            `TCTAAACCGTCGAGTTCGGCG`                                                  
  *aac (6')-Ib-cr*   Forward                   `TTGGAAGCGGGGACGGAM`               260 bp      58°C
  Reverse            `ACACGGCTGGACCATA`                                                       

### DNA sequencing {#sec006}

We sequenced the purified PCR products with an ABI 3730XL sequencer (Applied Biosystems, USA). We analysed the nucleic acid sequences using the Basic Local Alignment Search Tool available at the National Centre for Biotechnology database. We submitted the nucleic acid sequences to Genbank (accession numbers for ESBLs: MH745708, MH745709, MH745710, MH745711, MH745712, MH745713, MH745714, MH745715, MH745716 and PMQRs: MK761221, MK761222, MK761223, MK761224, MK761225, and MK761226).

Results {#sec007}
=======

Distribution of ESBL and quinolone resistance among isolates {#sec008}
------------------------------------------------------------

Of 1,841 urine samples, 133 had significant bacterial growth, defined as ≥10^5^ CFU/mL. Gram-negative bacilli accounted for 85% (113) of the isolates, including *E*. *coli* (n = 79), *K*. *pneumoniae* (n = 29), *Sphingomonas* (n = 3), *Enterobacter* (n = 1), and *Citrobacter* (n = 1) ([Fig 3](#pone.0232710.g003){ref-type="fig"}).

![Phenotypic distribution of ESBL and quinolone resistance among isolates.\
High levels of ESBL and quinolone resistance were observed among *E*. *coli* isolates. *K*. *pneumoniae* isolates demonstrated less but still substantial resistance.](pone.0232710.g003){#pone.0232710.g003}

Based on VITEK-2 determinations, we detected ESBL positivity in 65% (51) of *E*. *coli* isolates and 41% (12) of *K*. *pneumonia* isolates. Quinolone resistance was observed in 47% (37) of *E*. *coli* isolates, whereas only one isolate of *K*. *pneumoniae* demonstrated resistance to quinolones.

Resistance patterns to other antibiotics {#sec009}
----------------------------------------

We evaluated for resistance against individual antimicrobial agents separated by ESBL determination. Among ESBL-positive *E*.*coli* isolates, we observed the highest resistance against nalidixic acid (86%), which can signify reduced susceptibility to fluoroquinolones. High levels of resistance were also noted for ciprofloxacin (57%), trimethoprim/sulfamethoxazole (55%), and gentamicin (33%). Multi-drug resistance (resistance to at least 3 classes of antibiotics) was noted in 45% of ESBL-positive *E*. *coli* isolates ([Table 3](#pone.0232710.t003){ref-type="table"}).

10.1371/journal.pone.0232710.t003

###### Antimicrobial resistance patterns of *E*. *coli* isolates by ESBL positivity.

![](pone.0232710.t003){#pone.0232710.t003g}

  Antibiotic                          ESBL *E*. *coli* (n = 51)   Non-ESBL *E*. *coli* (n = 28)                                        
  ----------------------------------- --------------------------- ------------------------------- ------------ ------------ ---------- ------------
  Amoxicillin/Clavulanic acid         28 (56%)                    18 (36%)                        4 (8%)       26 (92.9%)   2 (7.1%)   \-
  Cefuroxime                          10 (20%)                    1 (2%)                          39 (78%)     25 (89.3%)   1 (3.6%)   2 (7.1%)
  Ceftriaxone                         13 (26%)                    2 (4%)                          35 (70%)     24 (88.9%)   1 (3.7%)   2 (7.4%)
  Piperacillin/Tazobactam             43 (86%)                    3 (6%)                          4 (8%)       25 (96.2%)   \-         1 (3.8%)
  Gentamicin                          34 (66.7%)                  \-                              17 (33.3%)   28 (100%)    \-         \-
  Nalidixic acid                      7 (14%)                     \-                              43 (86%)     11 (39.3%)   \-         17 (60.7%)
  Ciprofloxacin                       21 (41.2%)                  1 (2.0%)                        29 (56.9%)   20 (71.4%)   1 (3.6%)   7 (25%)
  Meropenem                           51 (100%)                   \-                              \-           28 (100%)    \-         \-
  Nitrofurantoin                      48 (96%)                    1 (2.0%)                        1 (2.0%)     25 (89.3%)   2 (7.1%)   1 (3.6%)
  Trimethoprim/sulfamethoxazole       23 (45.1%)                  \-                              28 (54.9%)   20 (76.9%)   \-         6 (23.1%)
  Multi-drug resistant (≥3 classes)                                                               23 (45.1%)                           0

Among ESBL-positive *K*. *pneumoniae* isolates, rates of resistance to other antibiotics was lower, though a substantial number of isolates demonstrated only intermediate susceptibility to nitrofurantoin (50%), a common treatment option for community-acquired UTIs. Resistance to other antimicrobial classes are shown in [Table 4](#pone.0232710.t004){ref-type="table"}. All the ESBL-positive *K*. *pneumoniae* isolates were sensitive to nalidixic acid and ciprofloxacin, and only one isolate demonstrated multi-drug resistance (8%).

10.1371/journal.pone.0232710.t004

###### Antimicrobial resistance patterns of *K*. *pneumoniae* isolates by ESBL positivity.

![](pone.0232710.t004){#pone.0232710.t004g}

  Antibiotic                          ESBL *K*. *pneumoniae* (n = 12)   Non-ESBL *K*. *pneumoniae* (n = 17)                                         
  ----------------------------------- --------------------------------- ------------------------------------- ------------ ------------ ----------- -----------
  Amoxicillin/Clavulanic acid         11 (91.7%)                        \-                                    1 (8.3%)     17 (100%)    \-          \-
  Cefuroxime                          3 (25%)                           \-                                    9 (75%)      17 (100%)    \-          \-
  Ceftriaxone                         2 (16.7%)                         \-                                    10 (83.3%)   17 (100%)    \-          \-
  Piperacillin/Tazobactam             12 (100%)                         \-                                    \-           17 (100%)    \-          \-
  Gentamicin                          11 (91.7%)                        \-                                    1 (8.3%)     17 (100%)    \-          \-
  Nalidixic acid                      12 (100%)                         \-                                    \-           15 (88.2%)   \-          2 (11.8%)
  Ciprofloxacin                       12 (100%)                         \-                                    \-           16 (94.1%)   \-          1 (5.9%)
  Meropenem                           12 (100%)                         \-                                    \-           17 (100%)    \-          \-
  Nitrofurantoin                      5 (41.7%)                         6 (50.0%)                             1 (8.3%)     12 (70.6%)   5 (29.4%)   \-
  Trimethoprim/sulfamethoxazole       12 (100%)                         \-                                    \-           17 (100%)    \-          \-
  Multi-drug resistant (≥3 classes)                                                                           1 (8.3%)                              0

Distribution of ESBL genes {#sec010}
--------------------------

We identified 63 phenotypically-confirmed ESBLs (51 *E*. *coli* and 12 *K*. *pneumoniae)*, which were genotypically characterized for ESBL genes (*CTX-M*, *SHV*, *and TEM*). Among these isolates, the most common ESBL gene was *TEM-1* in *E*. *coli* (62.7%) and *K*. *pneumoniae* (83.3%), followed by *CTX-M-15* as the second most prevalent gene at 35.2% and 25%, respectively ([Table 5](#pone.0232710.t005){ref-type="table"}). We found a co-occurrence of *CTX-M-15* and *TEM-1* genes in 23.8% of isolates and *TEM-1* and *SHV-38* genes in 4.8%. Overall 28.6% of isolates carried two resistance genes.

10.1371/journal.pone.0232710.t005

###### Frequency of ESBL genes among ESBL-producing *E*. *coli* and *K*. *pneumoniae*.

![](pone.0232710.t005){#pone.0232710.t005g}

  ESBL Gene          *E*. *coli* (n = 51)   *K*. *pneumoniae* (n = 12)
  ------------------ ---------------------- ----------------------------
  *CTX-M-15*         18 (35.2%)             3 (25.0%)
  *TEM-1*            32 (62.7%)             10 (83.3%)
  *SHV-38*           10 (19.6%)             2 (16.6%)
  *TEM-1+SHV-38*     3 (5.8%)               0
  *CTX-M-15+TEM-1*   12 (23.5%)             3 (25.0%)

Distribution of PMQR genes {#sec011}
--------------------------

We identified 43 phenotypically-confirmed quinolone-resistant ESBL *E*. *coli* strains, and we genotypically characterized 32 for PMQR genes. The most common gene in the present study was *qnrS* at 62.5% followed by *aac (6\')-Ib-cr* at 37.5% ([Table 6](#pone.0232710.t006){ref-type="table"}). *QnrA*, *qnrB*, and *qnrD* were not detected. Since all of the ESBL-positive *K*. *pneumoniae* were sensitive to quinolones they were not tested for PMQR genes.

10.1371/journal.pone.0232710.t006

###### Frequency of PMQR genes among quinolone-resistant, ESBL-positive *E*. *coli*.

![](pone.0232710.t006){#pone.0232710.t006g}

  PMQR Gene                 *E*. *coli* (n = 32)   Nalidixic acid resistance   Ciprofloxacin Resistance
  ------------------------- ---------------------- --------------------------- --------------------------
  *qnrA*                    0 (0%)                 0                           0
  *qnrB*                    0 (0%)                 0                           0
  *qnrD*                    0 (0%)                 0                           0
  *qnrS*                    20 (62.5%)             20                          15
  *aac (6\')-Ib-cr*         12 (37.5%)             9                           9
  *qnrS +aac (6\')-Ib-cr*   2 (6.25%)              9                           4

Discussion {#sec012}
==========

The aim of the study was to evaluate the prevalence of PMQR and ESBL-producing gram-negative organisms among primigravid women with bacteriuria. Pregnant women are an understudied population with regards to antimicrobial resistance, and very few studies have previously examined the prevalence of PMQR and ESBL genes among enterobacterial isolates from pregnant women \[[@pone.0232710.ref021]\]. However, the implications of the findings likely extend to uropathogen resistance profiles in the community given the absence of prior healthcare exposure in this population. The high overall rates of plasmid-mediated resistance in this study are cause for concern.

Since the early 2000s a change in epidemiology of ESBL-producing Enterobacteriaceae was observed with increasing reports of their occurrence in community-acquired infections \[[@pone.0232710.ref022]\]. We detected an overall prevalence of ESBL-producing *E*. *coli* isolates of 65% in this study with 48% phenotypic resistance to third-generation cephalosporins. This contrasts with studies published from 2011--2014 evaluating bacteriuria in pregnant women in India that found rates of *E*. *coli* resistance to cephalosporins as low as 0--14% \[[@pone.0232710.ref023], [@pone.0232710.ref024]\]. Similarly, a previous study of rectal *E*. *coli* isolates from pregnant women in India demonstrated 17--19% resistance to third-generation cephalosporins, with 86% of those isolates producing ESBLs, highlighting either the rapid spread of antibiotic resistance or substantial variations in local epidemiology \[[@pone.0232710.ref021]\].

The emergence of ESBL-producing Enterobacteriaceae was attributed to the spread of the *CTX-M* gene \[[@pone.0232710.ref022]\]. However, the most common ESBL gene in the present study was *TEM-1*, similar to findings from other studies in India \[[@pone.0232710.ref025]--[@pone.0232710.ref027]\]. Additionally, in our study a third of isolates carried more than one type of beta-lactamase gene, similar to prior reports that have demonstrated a frequent co-occurrence of ESBL genes \[[@pone.0232710.ref022], [@pone.0232710.ref027]\]. Overall, 84% percent of ceftriaxone-resistant isolates carried at least one ESBL gene. Several studies in India have shown *Klebsiella spp*. as the major ESBL producer \[[@pone.0232710.ref025], [@pone.0232710.ref026]\], though our study revealed greater ESBL positivity among *E*. *coli*, which has also been reflected in other studies \[[@pone.0232710.ref028]\].

We demonstrated a high level of quinolone resistance among ESBL-positive *E*. *coli*, supporting the co-transmission of resistance genes on plasmids. This has been seen in other studies in India where 61% of ciprofloxacin-resistant *E*. *coli* isolates demonstrated ESBL production \[[@pone.0232710.ref029]\]. Accordingly, multi-drug resistance was common in *E*. *coli*, though lower resistance was seen in *K*. *pneumoniae* isolates. As *E*. *coli* is one of the most common causes of bacteriuria in pregnant women as well as community-acquired UTIs, the clustering of resistance genes among *E*. *coli* isolates presents concerning therapeutic challenges.

Fluoroquinolone therapy is generally avoided in pregnant women because of safety concerns in developing foetuses, though it remains an important treatment for UTIs and other types of infections in non-pregnant individuals. Overall resistance to fluoroquinolones in this study both in ESBL and non-ESBL varied substantially between *E*. *coli* (45.1%) and *K*. *pneumonia* (3.6%). Qnr genes were detected in 86% of quinolone-resistant isolates. This is higher than another study from India that reported a prevalence of 50% among ciprofloxacin-resistant uropathogenic *E*. *coli* \[[@pone.0232710.ref029]\]. The total percentage of *E*. *coli* isolates harbouring qnr genes in this study, as shown in [Table 3](#pone.0232710.t003){ref-type="table"}, is also significantly higher compared to Brazil, Europe, the USA, and elsewhere in Asia \[[@pone.0232710.ref019], [@pone.0232710.ref030]--[@pone.0232710.ref035]\].

In this study, we only detected *qnrS* and *aac (6')-Ib-cr* genes in *E*. *coli*, with almost a quarter of isolates containing both genes. *QnrA*, *qnrB*, and *qnrC* were not found. Few studies in India reported PMQR genes among clinical isolates of Enterobacteriaceae, but the most prevalent gene reported has been *aac (6')-lb-cr* \[[@pone.0232710.ref021], [@pone.0232710.ref029], [@pone.0232710.ref036]\]. However, regionally *qnrS* has been found to be a major antimicrobial resistant gene in environmental samples in India \[[@pone.0232710.ref036]\]. Studies on *E*. *coli* strains showing higher prevalence of *qnrA* and *qnrB* have mostly been among clinical isolates from HCAIs \[[@pone.0232710.ref031]\].

The increased frequency of ESBL and PMQR genes detected in this study carries significant implications for the management of community-acquired infections and further spread of these plasmid-mediated resistance mechanisms through horizontal gene transfer to other bacterial classes. Additionally, it raises the question about what is driving this trend. Overuse and misuse of antibiotics has changed the landscape of resistance, but this study population has not been directly influenced by the typical risk factors such as recent antibiotic use or healthcare contact/hospitalization \[[@pone.0232710.ref021], [@pone.0232710.ref037], [@pone.0232710.ref038]\]. After eliminating the effects of healthcare, presence of resistant bacteria has been found to be most closely linked to low socioeconomic status \[[@pone.0232710.ref015]\]. In fact, a review of community-acquired UTIs found that exposure to food, animal, and environmental sources may predict UTIs caused by ESBL-producing *E*. *coli* \[[@pone.0232710.ref039]\]. This finding suggests that there are environmental selective pressures that are distinct from the healthcare setting, and contamination of the environment by biocides and antibiotic residues are increasing resistance in community flora \[[@pone.0232710.ref040]--[@pone.0232710.ref042]\].

Indeed, in a series of studies conducted near the present research site, high levels of fluoroquinolones have been detected in water and environmental sources as a result of contamination by pharmaceutical manufacturing effluent \[[@pone.0232710.ref043], [@pone.0232710.ref044]\]. Environmental contamination in particular selects for antibiotic resistance genes on mobile genetic elements because it promotes increased uptake of foreign DNA, which contributes to bacterial resilience under selective pressures \[[@pone.0232710.ref045], [@pone.0232710.ref046]\]. The findings of this study provide concerning evidence that these environmental processes may be spreading into human pathogens.

In conclusion, our study emphasizes the high prevalence of plasmid-mediated ESBL and quinolone resistance in community-acquired UTIs. While lower resistance was found in *K*. *pneumoniae* isolates compared with *E*. *coli*, overall abundance of drug resistance among uropathogens in this population is alarming. The findings of this study limit empiric treatment options for community-acquired UTI, including among pregnant women. Early detection of multi-drug-resistant isolates in routine microbiology laboratories is critical to avoid treatment failure and the complications thereof. Future surveillance and characterization of plasmids carrying multi-drug-resistance determinants could improve understanding of the origin and evolution of gram-negative bacterial resistance and inform infection control efforts.
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4\. Thank you for stating the following financial disclosure:

\'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\'

Please provide an amended Funding Statement that declares \*all\* the funding or sources of support received during this specific study (whether external or internal to your organization) as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now> Please state what role the funders took in the study.  If any authors received a salary from any of your funders, please state which authors and which funder. If the funders had no role, please state: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

c\. Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

6\. Please upload a copy of Supporting Information Table S1 which you refer to in your text on page 21.

7\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: It is mentioned that consent was taken for interview.(In addition, we administered surveys regarding community exposures at the time of enrollment) But there is no discussion on outcome of the interviews?

Appropriate statistical analysis has not been made to highlight the proportion of various genes for ESBLs in the isolates.

Sequencing outcomes have not been discussed.Was any mutation detected?

What is the explanation for isolates with undetected genes? No explanation has not been given.

Limitations of the study have not been discussed.

Reviewer \#2: as enclosed as attachment.

• In the methodology its mentioned survey. What kind of surveys were carried out among primigravid and what information was collected details needs to be included.

• During the discussion it has been mentioned that molecular epidemiology ESBL and quinolone producing gram negative drug resistant isolates in primigravid during first visit of primigravid antenatal clinic has been described in this manuscript. However that has not been the aim of the study.

• In conclusion also study emphasises on high prevalence of drug resistant to ESBL and quinolone in community acquired UTI. Which is not included in the aims.

• In the study there is no molecular epidemiology data provided so as to corroborate with discussion as mentioned on the line no 201 to 204.

• More over its only drug resistance study using different methods including molecular levels and gene detection.

• As the study has not been compared with any other groups or with previous year data title of the study is deceptive. Needs to be corrected.

Clarification on above points may be provided

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Reba Kanungo

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Submitted filename: Comments on uropathogens AMR.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0232710.r002

Author response to Decision Letter 0

7 Feb 2020

Comments on plasmid-mediated antibiotic resistance among uropathogens in primigravid women -- Hyderabad, India:

The above study was carried out with the aim of to evaluate the prevalence of plasmid-mediated-quinolone-resistance (PMQR) and extended-spectrum beta lactamase- (ESBL) producing gram-negative organisms among primigravid women with bacteriuria. This has been done to uncover the epidemiology of PMQR and ESBL 84 genes in gram-negative bacilli among primigravid women having urinary infections. Comments are given below:

• In the methodology its mentioned survey. What kind of surveys were carried out among primigravid and what information was collected details needs to be included.

Response to Reviewer:

A cross- sectional observational study was conducted at Gandhi Medical College and Hospital. The information collected details were included in the previous published paper. Reference number 15 in the present article.

Alsan M, Kammili N, Lakshmi J, Xing A, Khan A, Rani M, et al. Poverty and Community-Acquired Antimicrobial Resistance with Extended-Spectrum β-Lactamase--Producing Organisms, Hyderabad, India. EmergInfect Dis. 2018 Aug; 24(8):1490.

• During the discussion it has been mentioned that molecular epidemiology ESBL and quinolone producing gram negative drug resistant isolates in primigravid during first visit of primigravid antenatal clinic has been described in this manuscript. However that has not been the aim of the study.

Response to Reviewer:

Correction has been made and included in page 4 and 5, lines 85,86,87.

• In conclusion also study emphasises on high prevalence of drug resistant to ESBL and quinolone in community acquired UTI. Which is not included in the aims.

Response to Reviewer:

It has been included in page 4 and 5, lines 85,86,87.

• In the study there is no molecular epidemiology data provided so as to corroborate with discussion as mentioned on the line no 201 to 204.

Response to Reviewer:

The Molecular epidemiology data has been tabulated in tables 5 & 6, page no: 11 & 12.

• More over its only drug resistance study using different methods including molecular levels and gene detection.

Response to Reviewer:

Yes its drug resistance study using different methods including molecular levels and gene detection

• As the study has not been compared with any other groups or with previous year data title of the study is deceptive. Needs to be corrected.

Response to Reviewer:

Title has been changed included in the Title page.

10.1371/journal.pone.0232710.r003

Decision Letter 1

Karunasagar

Iddya

Academic Editor

© 2020 Iddya Karunasagar

2020

Iddya Karunasagar

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

23 Mar 2020

PONE-D-19-29203R1

Plasmid-mediated antibiotic resistance among uropathogens in primigravid women -- Hyderabad, India

PLOS ONE

Dear Dr Kammili,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

There are some minor comments marked on the text

==============================

We would appreciate receiving your revised manuscript by May 07 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Iddya Karunasagar

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Most of the reviewers comments have been addressed by the authors. There are some minor comments marked on the text

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The issues raised by the reviewer has been addressed adequately. The authors have responded to each of the queries raised by the reviewer and made necessary changes in the revised text.

Reviewer \#2: though the authors have incorporated replies to most of the queries but some of the queries are not addressed correctly. author needs to modify the same so as to make manuscript more meaningful. see the attchment for details.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Dr. Reba Kanungo MD,PhD Head of Microbiology Pondicherry Institute of Medical Sciences Puducherry-India

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: revised comments on uropathogen amr.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0232710.r004

Author response to Decision Letter 1

19 Apr 2020

1\. The beginning of the discussion has been changed to remove the first three lines and begin the discussion with the abstract aims, as suggested. See lines 208-209.

2\. In the discussion, we have added specific rates of resistance from other studies in India. See lines 227-229, 246-247, and 256-257.

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0232710.r005

Decision Letter 2

Karunasagar

Iddya

Academic Editor

© 2020 Iddya Karunasagar

2020

Iddya Karunasagar

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

21 Apr 2020

Plasmid-mediated antibiotic resistance among uropathogens in primigravid women -- Hyderabad, India

PONE-D-19-29203R2

Dear Dr. Kammili,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Iddya Karunasagar

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All reviewer comments addressed satisfactorily

Reviewers\' comments:

10.1371/journal.pone.0232710.r006

Acceptance letter

Karunasagar

Iddya

Academic Editor

© 2020 Iddya Karunasagar

2020

Iddya Karunasagar

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

28 Apr 2020

PONE-D-19-29203R2

Plasmid-mediated antibiotic resistance among uropathogens in primigravid women -- Hyderabad, India

Dear Dr. Kammili:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Iddya Karunasagar

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
